Pharmacological approaches to the treatment of COVID-19 patients
The current COVID-19 pandemic has presented unprecedented challenges to the world community. No effective therapies or vaccines have yet been established. Upon the basis of homologies to similar coronaviruses, several potential drug targets have been identified and are the focus of both laboratory and clinical investigation. The rationale for several of these drug candidates is presented in this review. Emerging clinical data has revealed that severe COVID-19 disease is associated with heightened inflammatory responses and a procoagulant state, suggesting that patient treatment strategies must extend beyond antiviral agents. Effective approaches to the treatment of vulnerable patients with comorbidities will render COVID-19 substantially more manageable.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:6 |
|---|---|
| Enthalten in: |
Journal of translational science - 6(2020), 6 vom: 29. Dez. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sowers, Lawrence C [VerfasserIn] |
|---|
| Themen: |
Antiviral |
|---|
| Anmerkungen: |
Date Revised 13.08.2022 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM316124133 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM316124133 | ||
| 003 | DE-627 | ||
| 005 | 20231225160412.0 | ||
| 007 | tu | ||
| 008 | 231225s2020 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n1053.xml |
| 035 | |a (DE-627)NLM316124133 | ||
| 035 | |a (NLM)33042589 | ||
| 035 | |a (PII)394 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sowers, Lawrence C |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pharmacological approaches to the treatment of COVID-19 patients |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Revised 13.08.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a The current COVID-19 pandemic has presented unprecedented challenges to the world community. No effective therapies or vaccines have yet been established. Upon the basis of homologies to similar coronaviruses, several potential drug targets have been identified and are the focus of both laboratory and clinical investigation. The rationale for several of these drug candidates is presented in this review. Emerging clinical data has revealed that severe COVID-19 disease is associated with heightened inflammatory responses and a procoagulant state, suggesting that patient treatment strategies must extend beyond antiviral agents. Effective approaches to the treatment of vulnerable patients with comorbidities will render COVID-19 substantially more manageable | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a antiviral | |
| 650 | 4 | |a coagulation | |
| 650 | 4 | |a coronavirus | |
| 650 | 4 | |a inflammation | |
| 700 | 1 | |a Blanton, Lucas S |e verfasserin |4 aut | |
| 700 | 1 | |a Weaver, Scott C |e verfasserin |4 aut | |
| 700 | 1 | |a Urban, Randall J |e verfasserin |4 aut | |
| 700 | 1 | |a Mouton, Charles P |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of translational science |d 2015 |g 6(2020), 6 vom: 29. Dez. |w (DE-627)NLM250399199 |x 2059-268X |7 nnns |
| 773 | 1 | 8 | |g volume:6 |g year:2020 |g number:6 |g day:29 |g month:12 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 6 |j 2020 |e 6 |b 29 |c 12 | ||